Rivus Pharmaceuticals
CompanyUnited States
Rivus Pharmaceuticals develops one asset, in phase 2 (HU6 in fatty liver disease). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $290M
- 2
- Trials
- 0
- Signals
Pipeline
1Controlled metabolic protonophore that uncouples oxidative phosphorylation to increase energy expenditure and reduce fat.
Phase 2, Small molecule, fatty liver disease, mash metabolic dysfunction associated steatohepatitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- Funding rounds and grants4
- People10
- Signals1
- Similar companies6